Get the Stockscreener App
1.64
3.53%
-0.06
After Hours:
1.65
0.01
+0.61%
Longeveron Inc stock is traded at $1.64, with a volume of 119.92K.
It is down -3.53% in the last 24 hours and up +4.46% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$1.70
Open:
$1.71
24h Volume:
119.92K
Relative Volume:
0.38
Market Cap:
$24.48M
Revenue:
$1.89M
Net Income/Loss:
$-17.92M
P/E Ratio:
-0.2451
EPS:
-6.69
Net Cash Flow:
$-15.62M
1W Performance:
+13.89%
1M Performance:
+4.46%
6M Performance:
-21.15%
1Y Performance:
-65.20%
1-Day Range:
$1.61
$1.74
1-Week Range:
$1.40
$1.76
52-Week Range:
$0.7707
$6.40
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
1.64 | 24.48M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia
Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times
Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks
Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq
Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study - StockTitan
Q1 Earnings Estimate for Longeveron Issued By Roth Capital - Defense World
Q1 Earnings Forecast for Longeveron Issued By HC Wainwright - Defense World
Q1 Earnings Forecast for Longeveron Issued By Roth Capital - Defense World
FY2025 EPS Estimates for Longeveron Reduced by Analyst - Defense World
Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript - MSN
Longeveron® to Present at the 37th Annual Roth Conference - The Manila Times
How Longeveron's Upcoming Roth Conference Appearance Could Spotlight Its Cellular Therapy Pipeline - StockTitan
Longeveron Inc. Reports Strong 2024 Financial Growth - TipRanks
Longeveron (NASDAQ:LGVN) Receives Buy Rating from HC Wainwright - Defense World
Longeveron Inc. Earnings Call: Growth and Challenges - TipRanks
Longeveron Inc (NASDAQ: LGVN) Declines -0.65%: This $22.55 million Stock Could Go Down -557.89% - Stocks Register
LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews
Earnings call transcript: Longeveron Q4 2024 sees revenue surge, stock gains - Investing.com Canada
Longeveron Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Can Longeveron's 237% Revenue Surge and Advanced Clinical Trial Transform Pediatric Heart Treatment? - StockTitan
LONGEVERON Earnings Preview: Recent $LGVN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Longeveron (LGVN) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Longeveron® Announces World Health Organization Approval of “laro - The National Law Review
LGVNRLongeveron Latest Stock News & Market Updates - StockTitan
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - The Manila Times
Longeveron Inc. to Announce Full-Year 2024 Financial Results and Company Update on February 28, 2025 - Nasdaq
Longeveron Cellular Therapy Granted International Non-Proprietary Name -February 18, 2025 at 10:33 am EST - Marketscreener.com
Longeveron’s Lomecel receives WHO non-proprietary name approval as laromestroce - TipRanks
Longeveron® Announces World Health Organization Approval of - GlobeNewswire
Breakthrough Alzheimer's Treatment Gets Official WHO RecognitionMajor Milestone for Rare Disease Therapy - StockTitan
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - Marketscreener.com
Biotech Breakthrough: Longeveron Reveals Latest Regenerative Medicine Advances at Major Conference - StockTitan
Longeveron announces board member resignation - MSN
Longeveron announces board member resignation By Investing.com - Investing.com South Africa
Longeveron Board Member Neil Hare Resigns - TipRanks
Geode Capital Management LLC Acquires 97,953 Shares of Longeveron Inc. (NASDAQ:LGVN) - Defense World
State Street Corp Takes Position in Longeveron Inc. (NASDAQ:LGVN) - Defense World
Longeveron (NASDAQ:LGVN) Stock Price Up 1.1% – Here’s What Happened - Defense World
Longeveron to Present at Biotech Showcase 2025 - The Manila Times
Longeveron CEO to Present at Biotech Showcase 2025: Spotlight on Regenerative Medicine Breakthroughs - StockTitan
Longeveron (NASDAQ:LGVN) Earns Buy Rating from Analysts at Roth Mkm - Defense World
Longeveron (NASDAQ:LGVN) Upgraded at Roth Capital - Defense World
Longeveron initiated with a Buy at Roth MKM - Yahoo Finance
Roth MKM Initiates Coverage of Longeveron (LGVN) with Buy Recommendation - MSN
Longeveron director Baluch Khoso sells $2,588 in stock By Investing.com - Investing.com Canada
Longeveron director Baluch Khoso sells $2,588 in stock - Investing.com
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):